Calcium Interactions

Calcium binds tightly to tetracycline in the gut, forming an insoluble chelate that cannot be absorbed. Dairy products and calcium supplements can reduce tetracycline absorption by 50 to 90 percent, often dropping serum levels below the threshold needed to treat infection.

Calcium binds alendronate in the gut and forms an insoluble chelate, drastically reducing absorption of an already poorly bioavailable bisphosphonate (oral bioavailability is only ~0.6%). Co-administration can render the osteoporosis drug clinically ineffective.

Calcium significantly reduces levothyroxine absorption

Calcium inhibits iron absorption by up to 60%

Calcium can bind to certain antibiotics and reduce their absorption

High-dose calcium (>600mg) can reduce zinc absorption

Excessive caffeine increases calcium excretion in urine.

Calcium salts taken together with atenolol form a complex in the gut that cuts atenolol's peak plasma level by roughly 51% and total exposure (AUC) by 32%, blunting its blood-pressure and heart-rate effects 12 hours later. The effect was first quantified in a 1981 pharmacokinetic study and is the main reason high-dose calcium and atenolol should be separated in time.

Thiazide diuretics increase renal tubular reabsorption of calcium and reduce urinary calcium excretion, which is therapeutically useful for preventing kidney stones and reducing bone loss. However, this calcium-sparing effect can produce hypercalcemia when combined with high-dose calcium supplements, vitamin D, or in patients with underlying primary hyperparathyroidism.

Calcium chelates doxycycline in the gut, forming an insoluble complex that cannot be absorbed. Co-administration with calcium supplements or dairy products can reduce doxycycline absorption by 50 to 80 percent.

Phenytoin reduces calcium absorption by accelerating vitamin D catabolism and by directly inhibiting active transcellular calcium transport in intestinal enterocytes; separately, calcium-containing antacids and supplements can chelate phenytoin in the gut and lower its absorption when taken simultaneously.

Omeprazole impairs absorption of calcium carbonate (the most common supplemental form) because dissolution and ionization require an acidic gastric environment. Long-term PPI use is associated with increased risk of hip, wrist, and spine fractures, prompting an FDA labeling change in 2010-2011.

Calcium carbonate antacids raise gastric pH above the threshold that ketoconazole needs to dissolve, reducing oral ketoconazole absorption and lowering antifungal blood concentrations.

Calcium and other divalent cations bind risedronate in the gut and form insoluble complexes, blocking absorption of a drug whose oral bioavailability is already very low (~0.6%). Co-administration can reduce the dose to subtherapeutic levels.

Glucocorticoids like prednisone impair intestinal calcium absorption and increase urinary calcium loss, contributing to negative calcium balance and accelerated bone loss. This is a depletion-and-displacement effect, not a chemical interaction in the gut.

Calcium salts (carbonate, citrate, acetate) can bind thyroid hormone in the gastrointestinal tract and reduce absorption of liothyronine (T3) much as they do with levothyroxine. This can blunt the effect of the dose and lead to suboptimal thyroid replacement.

Theoretically, high doses of supplemental calcium could blunt the vasodilatory effect of calcium channel blockers such as amlodipine, but controlled human data are limited. Drugs.com flags this as a minor monitor-only interaction with weak clinical evidence.

Calcium chelates levofloxacin in the gastrointestinal tract, reducing peak serum concentrations by 20 to 30 percent. While the area under the curve is less affected than with older fluoroquinolones, the drop in peak concentration can matter for organisms with MICs close to the breakpoint.

Vitamin K2 activates osteocalcin and matrix Gla protein, which bind calcium and direct it into the bone matrix while keeping it out of arterial walls. Calcium supplementation paired with adequate K2 supports bone density and reduces the risk of misplaced calcium in soft tissue.

Boron reduces urinary calcium excretion and supports the hydroxylation of vitamin D into its active form, which in turn enhances intestinal calcium absorption. Postmenopausal women taking 3 mg/day of boron have shown reduced urinary calcium loss and improved markers of calcium retention.

Calcium and magnesium work together in bone mineralization, muscle contraction, and nerve signaling, but they compete for absorption through the same intestinal transporters at high single doses. Maintaining a dietary calcium-to-magnesium intake ratio in the 2:1 to 3:1 range is associated with the highest bone mineral density and lowest osteoporosis risk.